{"entity":{"id":"nct07710885","kind":"trial","name":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer","aka":["FOENIX-BTC"],"tldr":"A phase 3 trial of Futibatinib, Zimberelimab, Durvalumab, Pembrolizumab, Gemcitabine and Cisplatin in biliary tract cancer, run by Taiho Pharmaceutical Co., Ltd., now recruiting.","summary":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer is a phase 3 interventional study registered as NCT07710885 by Taiho Pharmaceutical Co., Ltd., with 784 participants planned, started 2026-06-24 and due to reach its primary completion in 2030-04-30. Interventions recorded: Futibatinib, Zimberelimab, Durvalumab, Pembrolizumab, Gemcitabine and Cisplatin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07710885","url":"https://clinicaltrials.gov/study/NCT07710885"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","kinase-inhibitors","platinum"],"targets":[],"drugs":["futibatinib","zimberelimab","durvalumab","pembrolizumab","gemcitabine","cisplatin"],"companies":["araris"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07710885","phase":"3","setting":"A Phase 3, Randomized-Controlled, Open-Label, Multi-Regional, International Study of Futibatinib (TAS-120) and Zimberelimab (AB122) in Combination With Gemcitabine Plus Cisplatin Versus Durvalumab or Pembrolizumab in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers","sponsor":"Taiho Pharmaceutical Co., Ltd.","started":"2026-06-24","startedType":"actual","enrolled":784,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07710885/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"futibatinib","kind":"drug","name":"Futibatinib","route":"/drugs/futibatinib/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/"}],"company":[{"id":"araris","kind":"company","name":"Araris Biotech (Taiho)","route":"/companies/araris/"}],"idea":[{"id":"idea-btc-ctdna-fgfr-resistance","kind":"idea","name":"ctDNA-guided switching among FGFR inhibitors","route":"/ideas/idea-btc-ctdna-fgfr-resistance/"}]}}